Cite
HARVARD Citation
Kong, D. et al. (2022). Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. Leukemia & lymphoma. 63 (2), pp. 491-494. [Online].